Media
Press Releases
July 4, 2025
Lupin Launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States
July 1, 2025
Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
June 26, 2025
Lupin Launches Prucalopride Tablets in the United States
June 25, 2025
Lupin Receives Approval from U.S. FDA for Prucalopride Tablets
June 7, 2025
Lupin Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets
May 26, 2025
Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025
May 15, 2025
Lupin Receives Approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg
May 13, 2025
Lupin Launches Tolvaptan Tablets in the U.S. with 180-Day Exclusivity
May 8, 2025
Lupin Receives Approval from U.S. FDA for Raltegravir Tablets USP, 600 mg
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product
Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.